G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the peer-reviewed journal of Clinical Lung Cancer published the final pooled results from three clinical trials of COSELA™ (trilaciclib) in extensive-stage small cell lung cancer (ES-SCLC).
“Cancer patients have two major sources of physical suffering – the cancer itself and the side effects of chemotherapy,” said first author Jared Weiss, MD, associate professor of medicine in the division of oncology and member of the Lineberger Comprehensive Cancer Center, in a press announcement published in BioSpace News.
“Small cell tends to present with bulky and rapidly growing central chest disease, which can compress airways and major vessels leading to shortness of breath, cough, and pain. While chemotherapy is great at shrinking the cancer and relieving these symptoms, it comes at the cost of side effects. The most common side effects from chemotherapy are suppression of blood counts and the consequences of that – neutropenia, anemia and fatigue. Trilaciclib helps decrease these side effects which can help optimize quality of life. With trilaciclib added to standard therapy, my patients experience less hematologic toxicity, a reduced need for supportive care interventions and hospitalizations due to CIM or sepsis, and ultimately improvements in health-related quality of life domains, including fatigue, and physical and functional well-being.”
The Clinical Lung Cancer article, “Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase 2 Randomized, Double-Blind, Placebo-Controlled Studies” can be found here.
Read the press announcement here.